Site Expansion - Regional Roundup: Georgia
Regional Roundup: Georgia
Key cities and populations
Metropolitan Statistical Areas: Atlanta: 4,529,256; Augusta-Richmond County, GA-SC: 507,000; Savannah: 300,000; Columbus, GA-AL: 283,000; Macon: 224,846; Athens-Clarke County: 170,012
Targeted industries
Biosciences (oncology, cardiovascular, infectious disease, bio-nanotechnology), logistics, advanced telecommunications, software
Biopharm employment
10,000 private sector; 12,000 government & academia
Academia affiliated with biopharm industry
Emory University; Georgia State University; University of Georgia; Georgia Institute of Technology; Clark Atlanta University; Morehouse School of Medicine; Medical College of Georgia; Kennesaw State University; Mercer University
Primary business strengths
Business center of Southeast US; low cost of living and low cost of business; country's largest in-migration for Metro Atlanta; world's largest and busiest passenger airport; highly educated workforce; public health capital with headquarters for CDC, American Cancer Society, Arthritis Foundation, Carter Center, and other centers
Tax and other incentives
Customized competitive incentive packages; state bioscience seed fund; various tax credits; state research funding via Georgia Research Alliance and Georgia Cancer Coalition; QuickStart customized state-funding training program
BioClusters
Metro Atlanta: over 75% of industry located in Metro Atlanta, primarily within the city and northern suburbs. Approximately 150 bioscience companies;
Athens-Clarke County: approximately 15 companies, many affiliated with University of Georgia;
Augusta-Richmond County: new bioscience incubator emerging at Medical College of Georgia
State commitment to biopharm industry and future plans for its growth
Over $350 million in state-supported research via Georgia Research Alliance; $1 billion Georgia Cancer Coalition; state Bioscience Seed Capital Fund; dedicated Office of Science and Technology; customized biopharm training paid by state QuickStart program; various industry funding programs via University System of Georgia; initiatives to continue statewide industry growth include several planned bio-parks in metro Atlanta, Augusta, and Athens; over 20,000 biopharm private sector employees expected by 2010
State- and regional-level contacts
Georgia Biomedical Partnership
Articles in this issue
Site Expansion - Regional Roundup: Georgia
Site Expansion - Regional Round-Up: Florida
A Protocol for Trademark Protection
Technology Licensing — From First Steps to Executing a Plan
Integrating QSIT into Quality Plans
Big Pharma And Investors Eye Australian Bio-Innovation Powerhouse
Correlating the Results from Chemistry Analyzers
Regulatory Beat: FDA: Manufacturing Innovation Can Boost R&D
Final Word: PEGylation — A "Sunset" Technology?
After the Consent Decree — An Uphill Battle for Affected Companies
Wall Street Gets Personal
Oral Delivery And Recombinant Production Of Peptide Hormones
Recent Videos
Related Content
International Women’s Day 2025: A Promising Future for Gender Diversity in Pharma
March 8th 2025Article
In an interview with BioPharm International®, Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Biotech EG 427 Raises €27 Million in Series B Funding to Advance Lead Genetic Medicine Candidate
February 24th 2025Article
Co-led by Andera Partners and Bpifrance, the Series B financing will go toward an ongoing Phase Ib/IIa clinical study for EG 427’s lead candidate and to advance the company’s genetic medicines platform.
